抑制表观遗传激活的miR-483-5p/IGF-2通路可快速降低脑膜瘤肿瘤细胞活力
本研究通过小RNA测序发现脑膜瘤中miR-483-5p呈高级别依赖性高表达,并与其宿主基因IGF-2的mRNA和蛋白高表达相关。抑制miR-483-5p或使用抗IGF-2中和抗体可减少培养脑膜瘤细胞生长,而IGF1R小分子酪氨酸激酶抑制剂可快速降低肿瘤来源细胞活力。结论认为脑膜瘤细胞生长关键依赖自分泌miR-483/IGF-2刺激,IGF-2通路是可行的治疗靶点。
要点
- 脑膜瘤样本中miR-483-5p高表达且与级别相关,伴IGF-2 mRNA和蛋白高表达。
- 抑制miR-483-5p减少培养脑膜瘤细胞生长,miR-483模拟物增加细胞增殖。
- 抗IGF-2中和抗体减少脑膜瘤细胞增殖,IGF1R抑制剂快速降低肿瘤来源细胞活力。
核心结论
- 脑膜瘤细胞生长关键依赖自分泌miR-483/IGF-2刺激,IGF-2通路是可行的脑膜瘤治疗靶点。
研究设计与样本
- 对脑膜瘤肿瘤样本进行小RNA测序以研究microRNA表达随级别的变化,并通过染色质标记、qRT-PCR和蛋白质印迹分析基因表达。
- 在脑膜瘤肿瘤来源的原代细胞培养中评估miRNA调控、抗IGF-2中和抗体及IGF1R抑制剂的作用。
主要发现
- 脑膜瘤肿瘤样本显示miR-483-5p高表达且与级别相关,并与其宿主基因IGF-2的mRNA和蛋白高表达相关。
- 抑制miR-483-5p减少培养脑膜瘤细胞生长,而miR-483模拟物增加细胞增殖。
- 用抗IGF-2中和抗体抑制该通路减少脑膜瘤细胞增殖。
- 小分子酪氨酸激酶抑制剂阻断IGF-2受体(IGF1R)导致培养的脑膜瘤肿瘤来源细胞活力快速丧失,提示自分泌IGF-2反馈对脑膜瘤肿瘤细胞存活和生长是必需的。
- 细胞实验中GSK1838705A和ceritinib的IGF1R抑制IC50及现有药代动力学数据预测可在体内达到有效药物浓度,作为脑膜瘤的新医学治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Meningioma is the most common primary central nervous system tumor often causing serious complications, and presently no medical treatment is available. The goal of this study was to discover miRNAs dysregulated in meningioma, and explore miRNA-associated pathways amenable for therapeutic interventions. METHODS: Small RNA sequencing was performed on meningioma tumor samples to study grade-dependent changes in microRNA expression. Gene expression was analyzed by chromatin marks, qRT-PCR and western blot. miRNA modulation, anti-IGF-2 neutralizing antibodies, and inhibitors against IGF1R were evaluated in a tumor-derived primary cultures of meningioma cells. RESULTS: Meningioma tumor samples showed high, grade-dependent expression of miR-483-5p, associated with high mRNA and protein expression of its host gene IGF-2. Inhibition of miR-483-5p reduced the growth of cultured meningioma cells, whereas a miR-483 mimic increased cell proliferation. Similarly, inhibition of this pathway with anti-IGF-2 neutralizing antibodies reduced meningioma cell proliferation. Small molecule tyrosine kinase inhibitor blockade of the IGF-2 receptor (IGF1R) resulted in rapid loss of viability of cultured meningioma tumor-derived cells, suggesting that autocrine IGF-2 feedback is obligatory for meningioma tumor cell survival and growth. The observed IGF1R-inhibitory IC50 for GSK1838705A and ceritinib in cell-based assays along with the available pharmacokinetics data predicted that effective drug concentration could be achieved in vivo as a new medical treatment of meningioma. CONCLUSION: Meningioma cell growth is critically dependent on autocrine miR-483/IGF-2 stimulation and the IGF-2 pathway provides a feasible meningioma treatment target.
引用
- Uhlmann EJ, Mackel CE, Deforzh E, et al. Inhibition of the epigenetically activated miR-483-5p/IGF-2 pathway results in rapid loss of meningioma tumor cell viability. J Neurooncol. 2023. PMID: 36809604. doi:10.1007/s11060-023-04264-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。